Johnson & Johnson MedTech (NYSE: JNJ) announced that it received CE mark approval for its dual-energy ThermoCool SmartTouch ...
Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...
The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.
Johnson & Johnson’s JNJ MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to ...
The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.
Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of ...
After a busy 2024, experts called out competition in soft tissue robotics, uncertainty from a Trump White House and continued ...